TELOZCEND Trademark

Trademark Overview

On Monday, February 2, 2026, a trademark application was filed for TELOZCEND with the United States Patent and Trademark Office. The USPTO has given the TELOZCEND trademark a serial number of 99627989. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Monday, February 2, 2026. This trademark is owned by Elixirgen Therapeutics, Inc.. The TELOZCEND trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells
telozcend

General Information

Serial Number99627989
Word MarkTELOZCEND
Filing DateMonday, February 2, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateMonday, February 2, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 2, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameElixirgen Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBaltimore, MD 21205

Trademark Events

Event DateEvent Description
Monday, February 2, 2026NEW APPLICATION ENTERED
Monday, February 2, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 2, 2026APPLICATION FILING RECEIPT MAILED

Related Keywords

telozcend blood cells pharmaceutical preparations treatment treated vectors containing telomeres proteins